BR0203501A - Formulações de multipartìculas biomoduladas - Google Patents

Formulações de multipartìculas biomoduladas

Info

Publication number
BR0203501A
BR0203501A BR0203501-4A BR0203501A BR0203501A BR 0203501 A BR0203501 A BR 0203501A BR 0203501 A BR0203501 A BR 0203501A BR 0203501 A BR0203501 A BR 0203501A
Authority
BR
Brazil
Prior art keywords
formulations
biomodulated
multiparticle
multiparticle formulations
release rate
Prior art date
Application number
BR0203501-4A
Other languages
English (en)
Inventor
Anne Billotte
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of BR0203501A publication Critical patent/BR0203501A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)

Abstract

"FORMULAçõES DE MULTIPARTìCULAS BIOMODULADAS". A presente invenção refere-se com os meios para ajuste da biodisponibilidade da atorvastatina de cálcio por modulação da sua taxa de liberação de formulações de multipartículas e com formulações de multipartículas, especialmente comprimidos e cápsulas, tendo a referida taxa de liberação modulada.
BR0203501-4A 2001-09-04 2002-08-30 Formulações de multipartìculas biomoduladas BR0203501A (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0121436.0A GB0121436D0 (en) 2001-09-04 2001-09-04 Biomodulated multiparticulate formulations

Publications (1)

Publication Number Publication Date
BR0203501A true BR0203501A (pt) 2003-05-20

Family

ID=9921522

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0203501-4A BR0203501A (pt) 2001-09-04 2002-08-30 Formulações de multipartìculas biomoduladas

Country Status (6)

Country Link
EP (1) EP1287821A1 (pt)
JP (1) JP2003128544A (pt)
BR (1) BR0203501A (pt)
CA (1) CA2400565A1 (pt)
GB (1) GB0121436D0 (pt)
MX (1) MXPA02008059A (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030190343A1 (en) * 2002-03-05 2003-10-09 Pfizer Inc. Palatable pharmaceutical compositions for companion animals
CA2465693A1 (en) * 2003-06-12 2004-12-12 Warner-Lambert Company Llc Pharmaceutical compositions of atorvastatin
JP3821139B2 (ja) * 2004-05-14 2006-09-13 コニカミノルタビジネステクノロジーズ株式会社 データ出力システム、およびデータ出力装置
EP1825848A3 (de) * 2006-02-10 2010-03-03 Stada Arzneimittel Ag Stabile pharmazeutische Zusammensetzungen umfassend einen HMG-CoA-Reduktase Inhibitor
EP1818050A1 (de) * 2006-02-10 2007-08-15 Stada Arzneimittel Ag Stabile pharmazeutische Zusammensetzungen umfassend einen HMG-CoA-Reduktase Inhibitor
BRPI0920170A2 (pt) 2008-10-17 2016-06-21 Metabolex Inc métodos para diminuir a quantidade de partículas ldl pequenas e densas e de níveis de triglicerídeos e ldl no sangue em um humano, e para identificar um indivíduo candidato para tratamento com um composto ou um sal, prodroga ou isômero do mesmo, composto ou um sal, prodroga ou isômero do mesmo, e método.
WO2010093285A1 (en) * 2009-02-12 2010-08-19 Aduro Material Ab Composition comprising biodegradable carrier for controlled drug delivery
WO2012042951A1 (ja) * 2010-09-30 2012-04-05 アステラス製薬株式会社 アトルバスタチン含有医薬錠剤
JP2013231011A (ja) * 2012-05-01 2013-11-14 Sawai Pharmaceutical Co Ltd アトルバスタチン含有医薬組成物およびそれを用いた口腔内崩壊錠
CN108421045B (zh) * 2018-04-02 2021-09-24 北京海晶生物医药科技有限公司 一种阿托伐他汀钙组合物、制剂及其制备方法
CN110151721B (zh) * 2019-06-10 2021-11-12 乐普制药科技有限公司 一种含有阿托伐他汀钙的片剂及其制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI94339C (fi) * 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
JP3254219B2 (ja) * 1993-01-19 2002-02-04 ワーナー−ランバート・コンパニー 安定な経口用のｃｉ−９８１製剤およびその製法
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
EP1272181A2 (en) * 2000-04-13 2003-01-08 Synthon B.V. Modified release formulations containing a hypnotic agent

Also Published As

Publication number Publication date
EP1287821A1 (en) 2003-03-05
CA2400565A1 (en) 2003-03-04
JP2003128544A (ja) 2003-05-08
MXPA02008059A (es) 2003-04-09
GB0121436D0 (en) 2001-10-24

Similar Documents

Publication Publication Date Title
BR0213355A (pt) composições farmacêuticas
MXPA02003933A (es) Microcapsulas para la estabilizacion de productos cosmeticos, farmaceuticos o de alimentacion.
PT1155692E (pt) Utilizacao de paclitaxel estabilizado com albumina para a preparacao de um farmaco para o tratamento de tumores solidos e o farmaco assim obtido
WO2002006218A3 (en) STABILIZED 1α-HYDROXY VITAMIN D
EP1402067A4 (en) HS2STS AS P53 PATH MODIFICATORS AND USE METHOD
BR0112589A (pt) Derivados de heteroarila e sua aplicação como medicamento
BR0114410A (pt) Associação de um antagonista de receptor cb1 e de sibutramina, as composições farmacêuticas que os contêm e a respectiva utilização para o tratamento da obesidade
HN2001000281A (es) Nuevas imidazotriazinonas sustituidas
CU23043A1 (es) Composicion farmaceutica que contiene factor de crecimiento epidrmico (egf) para la prevencion de la amputacion de pie diabetico.
WO2001080873A3 (en) Thrombopoietin receptor modulating peptide
BR0110387B1 (pt) cápsula de um dispositivo para o fechamento de uma garrafa.
SV1999000060A (es) Procedimiento para la preparacion de (s,s)-bencil-2,8-diazabiciclo 4.3.0 nonano ref. 32965-sv
BR0212931A (pt) Composição farmacêutica de liberação prolongada contendo metformina
EP0980864A3 (en) Sulphonamide derivatives
PT1355906E (pt) Derivados de 2h-1-benzopirano processos para a sua preparacao e as suas composicoes farmaceuticas
ES2160978T3 (es) Composiciones farmaceuticas estabilizadas y procedimiento para su preparacion.
BR0105906A (pt) Dispositivo de ativação
BR0314838A (pt) Sistema de liberação controlada, e, processo para preparar comprimidos de liberação controlada de temozolomida
ES2170922T3 (es) Composicion farmaceutica a base de matrices lipofilas estabilizadas para la liberacion controlada de principios activos.
ATE336891T1 (de) Pharmazeutisches freigabekonstrukt zur magenretention
BR0313745A (pt) Apresentação farmacêutica de liberação controlada de nitrofurantoina e processo para sua preparação
WO1999043285A3 (en) Sulphonamide derivatives
BR9905096A (pt) Dispositivo de comando para uma embreagem de fricção
BRPI0206841B8 (pt) aplicação de depsipeptídeo cíclico
BR0008197A (pt) Microcápsulas para a liberação prolongada de fármacos

Legal Events

Date Code Title Description
B08F Application fees: dismissal - article 86 of industrial property law

Free format text: REFERENTE 7A. E 8A. ANUIDADE(S).

B08K Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87)

Free format text: REFERENTE AO DESPACHO PUBLICADO NA RPI 2103 DE 26/04/2011.